The EVOPACS trial was recently published in the JACC

EVOPACS was an investigator-initiated, double-blind trial comparing Evolocumab vs Placebo treatment in the management of LDL levels, on the background of a high-intensity statin treatment of 40mg atorvastatin. The primary endpoint was calculated LDL-C reduction (%) over an eight week time period. The mean difference in calculated LDL-C change was -40.7% in favour of Evolocumab compared to Placebo. 2mt Ulm provided the Webspirit Data capture system, CTU Bern was involved in Data Quality surveillance and Statistical analyses. See for further reading: http://www.onlinejacc.org/content/early/2019/07/31/j.jacc.2019.08.010